Daniel H Solomon1,2, Chang Xu3, Jamie Collins4, Seoyoung C Kim3,5, Elena Losina4, Vincent Yau6, Fredrik D Johansson7. 1. Division of Rheumatology, Brigham and Women's Hospital, 60 Fenwood Road, Boston, MA, 02115, USA. dsolomon@bwh.harvard.edu. 2. Division of Pharmacoepidemiology, Brigham and Women's Hospital, Boston, USA. dsolomon@bwh.harvard.edu. 3. Division of Rheumatology, Brigham and Women's Hospital, 60 Fenwood Road, Boston, MA, 02115, USA. 4. Department of Orthopaedic Surgery, Brigham and Women's Hospital, Boston, USA. 5. Division of Pharmacoepidemiology, Brigham and Women's Hospital, Boston, USA. 6. Brigham and Women's Hospital, Genentech, San Francisco, California, USA. 7. Chalmers University of Technology, Gothenburg, Sweden.
Abstract
BACKGROUND: There are numerous non-biologic and biologic disease-modifying anti-rheumatic drugs (bDMARDs) for rheumatoid arthritis (RA). Typical sequences of bDMARDs are not clear. Future treatment policies and trials should be informed by quantitative estimates of current treatment practice. METHODS: We used data from Corrona, a large real-world RA registry, to develop a method for quantifying sequential patterns in treatment with bDMARDs. As a proof of concept, we study patients who eventually use tocilizumab monotherapy (TCZm), an IL-6 antagonist with similar benefits used as monotherapy or in combination. Patients starting a bDMARD were included and were followed using a discrete-state Markov model, observing changes in treatments every 6 months and determining whether they used TCZm. A supervised machine learning algorithm was then employed to determine longitudinal patient factors associated with TCZm use. RESULTS: 7300 patients starting a bDMARD were followed for up to 5 years. Their median age was 58 years, 78% were female, median disease duration was 5 years, and 57% were seropositive. During follow-up, 287 (3.9%) reported use of TCZm with median time until use of 25.6 (11.5, 56.0) months. Eighty-two percent of TCZm use began within 3 years of starting any bDMARD. Ninety-three percent of TCZm users switched from TCZ combination, a TNF inhibitor, or another bDMARD. Very few patients are given TCZm as their first DMARD (0.6%). Variables associated with the use of TCZm included prior use of TCZ combination therapy, older age, longer disease duration, seronegative, higher disease activity, and no prior use of a TNF inhibitor. CONCLUSIONS: Improved understanding of treatment sequences in RA may help personalize care. These methods may help optimize treatment decisions using large-scale real-world data.
BACKGROUND: There are numerous non-biologic and biologic disease-modifying anti-rheumatic drugs (bDMARDs) for rheumatoid arthritis (RA). Typical sequences of bDMARDs are not clear. Future treatment policies and trials should be informed by quantitative estimates of current treatment practice. METHODS: We used data from Corrona, a large real-world RA registry, to develop a method for quantifying sequential patterns in treatment with bDMARDs. As a proof of concept, we study patients who eventually use tocilizumab monotherapy (TCZm), an IL-6 antagonist with similar benefits used as monotherapy or in combination. Patients starting a bDMARD were included and were followed using a discrete-state Markov model, observing changes in treatments every 6 months and determining whether they used TCZm. A supervised machine learning algorithm was then employed to determine longitudinalpatient factors associated with TCZm use. RESULTS: 7300 patients starting a bDMARD were followed for up to 5 years. Their median age was 58 years, 78% were female, median disease duration was 5 years, and 57% were seropositive. During follow-up, 287 (3.9%) reported use of TCZm with median time until use of 25.6 (11.5, 56.0) months. Eighty-two percent of TCZm use began within 3 years of starting any bDMARD. Ninety-three percent of TCZm users switched from TCZ combination, a TNF inhibitor, or another bDMARD. Very few patients are given TCZm as their first DMARD (0.6%). Variables associated with the use of TCZm included prior use of TCZ combination therapy, older age, longer disease duration, seronegative, higher disease activity, and no prior use of a TNF inhibitor. CONCLUSIONS: Improved understanding of treatment sequences in RA may help personalize care. These methods may help optimize treatment decisions using large-scale real-world data.
Authors: Aliza R Karpes Matusevich; Zhigang Duan; Hui Zhao; Lincy S Lal; Wenyaw Chan; María E Suarez-Almazor; Sharon H Giordano; J Michael Swint; Maria A Lopez-Olivo Journal: Arthritis Care Res (Hoboken) Date: 2020-06-17 Impact factor: 4.794
Authors: Cem Gabay; Paul Emery; Ronald van Vollenhoven; Ara Dikranian; Rieke Alten; Karel Pavelka; Micki Klearman; David Musselman; Sunil Agarwal; Jennifer Green; Arthur Kavanaugh Journal: Lancet Date: 2013-03-18 Impact factor: 79.321
Authors: G Jones; A Sebba; J Gu; M B Lowenstein; A Calvo; J J Gomez-Reino; D A Siri; M Tomsic; E Alecock; T Woodworth; M C Genovese Journal: Ann Rheum Dis Date: 2010-01 Impact factor: 19.103
Authors: Maxime Dougados; Karsten Kissel; Philip G Conaghan; Emilio Martin Mola; Georg Schett; Roberto Gerli; Michael Sejer Hansen; Howard Amital; Ricardo M Xavier; Orrin Troum; Corrado Bernasconi; T W J Huizinga Journal: Ann Rheum Dis Date: 2014-01-28 Impact factor: 19.103